Abstract
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Current Respiratory Medicine Reviews
Title:An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
Volume: 13 Issue: 1
Author(s): Amelia Licari , Riccardo Castagnoli, Elisa Panfili, Alessia Marseglia, Ilaria Brambilla and Gian Luigi Marseglia*
Affiliation:
- Department of Pediatrics, University of Pavia, Pavia,Italy
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Abstract: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Export Options
About this article
Cite this article as:
Licari Amelia , Castagnoli Riccardo , Panfili Elisa , Marseglia Alessia , Brambilla Ilaria and Luigi Marseglia Gian *, An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases, Current Respiratory Medicine Reviews 2017; 13 (1) . https://dx.doi.org/10.2174/1573398X13666170616110738
DOI https://dx.doi.org/10.2174/1573398X13666170616110738 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Proteome Profiling to Identify Proteins Promoting Pathogenesis of Non-atopic Asthma
Protein & Peptide Letters Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets HPLC-NMR Chemical Profiling of the Australian Carnivorous Plant, Drosera erythrohiza subspecies magna
The Natural Products Journal The Discovery of VLA-4 Antagonists
Current Topics in Medicinal Chemistry Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Sulfur Dioxide: a Novel Gaseous Signal in the Regulation of Cardiovascular Functions
Mini-Reviews in Medicinal Chemistry Crosstalk Between Histamine and T Cells in Allergic Diseases
Current Immunology Reviews (Discontinued) Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Optimal Dosing Design for Antibiotic Therapy in the Elderly: A Pharmacokinetic and Pharmacodynamic Perspective
Recent Patents on Anti-Infective Drug Discovery LC-MS/MS Identification and Structural Characterization of Main Biodegradation Products of Nitroproston - A Novel Prostaglandin-based Pharmaceutical Compound
Drug Metabolism Letters Leukotrienes, Antileukotrienes and Asthma
Mini-Reviews in Medicinal Chemistry Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions
Current Drug Targets Dietary Antioxidants Significantly Reduced Phorbol Myristate Acetate Induced Oxidative Stress of Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis
Current Rheumatology Reviews HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c
Current Drug Delivery Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design